Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

IF 3.8 2区 医学 Q2 ONCOLOGY Current Treatment Options in Oncology Pub Date : 2024-04-27 DOI:10.1007/s11864-024-01203-6
Ziyu Kuang, Miao Kong, Ningzhe Yan, Xinyi Ma, Min Wu, Jie Li
{"title":"Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods","authors":"Ziyu Kuang, Miao Kong, Ningzhe Yan, Xinyi Ma, Min Wu, Jie Li","doi":"10.1007/s11864-024-01203-6","DOIUrl":null,"url":null,"abstract":"<p>Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"13 1","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01203-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
精准心脏病肿瘤学:基于 Omics 的诊断方法的最新进展
心脏病肿瘤学是一个新兴的跨学科领域,致力于早期检测和治疗与抗癌治疗相关的不良心血管事件,而目前抗癌治疗相关心血管毒性(CTR-CVT)的临床管理仍然受到缺乏详细表型数据的限制。然而,随着精准医疗的发展,特别是利用基于omics的方法发现敏感的疾病生物标志物,利用深度表型诊断CTR-CVT的前景已经出现。未来,将各种全局组学方法产生的信息结合起来,可以拓展心脏肿瘤学的临床实践。在这篇综述中,我们展示了全息方法如何提高我们对 CTR-CVT 深度表型的理解,讨论了用于 CTR-CVT 诊断的现有全息方法的积极和消极方面,并概述了如何将多组全息数据整合到个体化监测和治疗中。这将为降低癌症患者和幸存者的心血管发病率和死亡率提供一条可靠的技术路线。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.10
自引率
0.00%
发文量
113
审稿时长
>12 weeks
期刊介绍: This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.
期刊最新文献
New Therapeutic Targets in RAS Wild-type Pancreatic Cancer. Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease? Community Palliative Care: What are the Best Models? Contemporary Review of Adenocarcinoma of the Cervix. Updates in Treatment of HER2-positive Metastatic Breast Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1